非小细胞肺癌和肺结核中血清BCAR1水平的临床意义

探讨血清BCAR1水平在非小细胞肺癌和肺结核中的临床意义。方法:采用酶联免疫试剂方法（ELISA）检测2009年3月至2010年5月期间65例非小细胞肺癌（NSCLC），26例肺良性肿瘤（炎性假瘤15例、错构瘤7例、纤维瘤4例），30例肺结核患者（结核瘤17例，空洞型肺结核13例），40例正常人血清BCAR1水平。结果:NSCLC组血清BCAR1水平高于肺良性肿瘤组和正常对照组（P<0.001），而与肺结核组无显著差异（P>0.05）；血清BCAR1水平与性别、年龄和淋巴结转移无关（P>0.05）；与鳞癌和腺癌病理类型无关（P>0.05），支气管肺泡癌BCAR1血清水平低于其它类型NSCLC（P=0.02）；BCAR1血清水平随着临床分期增加有逐渐递增的趋势；BCAR1血清水平在切除肿瘤后其血清水平降低；肺结核组BCAR1血清水平高于正常对照组和肺良性肿瘤组（P<0.001），与结核病变的直径呈正相关（rs=0.92，P<0.001），切除结核病变后其血清水平下降，空洞型肺结核血清中BCAR1水平高于结核瘤（P<0.001）；肺良性肿瘤组和正常对照组血清BCAR1水平无显著性差异（P>0.05）。结论:血清BCAR1可以作为NSCLC和肺结核诊断、了解病情进展和判断治疗效果新指标。 

Clinical Significance of Serum BCAR1 Levels in Non-Small Cell Lung Cancer and PulmonaryTuberculosis

To evaluate the clinical significance of serum BCAR1 levels in non-small cell lung cancer ( NSCLC ) and pulmonary tuberculosis. Methods: An enzyme-linked immunosorbent assay ( ELISA ) was used to determine the serum BCAR1 levels in 65 patients with NSCLC, 26 with benign pulmonary tumors ( 15 inflammatory pseudotumors, 7 hamartomas, and 4 fibroid tumors ), 30 with pulmonary tuberculosis ( 17 tuberculomas and 13 cavitary pulmonary tuberculosis ), and 40 healthy volunteers who were admitted to the Daping Hospital, Chongqing, China between March 2009 and May 2010. Results: The serum BCAR1 levels were significantly higher in the NSCLC group than in the benign pulmonary tumor and the healthy control group ( P < 0.001 ). Nevertheless, there were no significant differences between the NSCLC group and the pulmonary tuberculosis group ( P > 0.05 ). The serum BCAR1 levels did not correlate with the age, gender, or lymph node metastasis ( P > 0.05 ). Although there were no significant differences in the serum BCAR1 levels between adenocarcinoma and squamous carcinoma ( P > 0.05 ), the serum BCAR1 levels were significantly lower in the cases with bronchioloalveolar carcinoma than with the other subtypes of NSCLCs ( P = 0.02 ). The serum BCAR1 levels were gradually increased with the progression of tumor staging and then was decreased after the removal of the tumors. The serum BCAR1 levels were obviously higher in the pulmonary tuberculosis group than in the benign pulmonary tumors group and the healthy controls ( P < 0.001 ) and were positively correlated with the diameter of the tuberculosis lesion ( rs = 0.92, P < 0.001 ). The serum BCAR1 levels? were decreased after the removal of the tuberculous lesions. The serum BCAR1 levels were higher in the cavitary pulmonary tuberculosis group than in the tuberculoma group ( P < 0.001 ). There were no appreciable differences in the serum BCAR1 levels between the benign pulmonary tumor group and the healthy controls ( P > 0.05 ). Conclusion: Serum BCAR1 can be used as a marker for diagnosing and assessing the progression of NSCLC, as well as determining the therapeutic efficacy of treatment for NSCLC and pulmonary tuberculosis.